Long-term favorable prognosis in late onset dominant distal titinopathy: Tibial muscular dystrophy.
muscle disorders
natural history
retrospective study
tibial muscular dystrophy
titin
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
revised:
15
09
2022
received:
19
07
2022
accepted:
11
10
2022
pubmed:
25
1
2023
medline:
8
3
2023
entrez:
24
1
2023
Statut:
ppublish
Résumé
Tibial muscular dystrophy (TMD) is a dominant late onset distal titinopathy. It was first described in Finnish patients 3 decades ago. TMD patients with several other TTN mutations occur in many European populations. In this retrospective study, we were able to obtain longitudinal follow-up data of the disease progression over 15 years in 137 TMD patients. We retrieved clinical data retrospectively from three examinations spanning a period of 15 years. The data were analyzed in R. Frequencies, percentages, and median values were used to describe data. Probability values were determined with the chi-squared test. In the cohort, the first symptoms were walking difficulties (97.8%) and weakness in distal lower limbs (98.5%). The progression of the weakness in distal lower limbs was moderate, and in the proximal lower limbs and proximal upper limbs it was mild. The distal upper limbs were not affected. Magnetic resonance imaging results indicated fatty degeneration preferentially in lower leg anterior muscles, gluteus minimus, and hamstring muscles. Serum creatine kinase values in the cohort were mostly normal (40.7%) or mildly elevated (53.7%). The data suggest that 50% of patients need walking aids by the age of 88 years. Despite individual variability of severity, the overall disability due to walking difficulties and upper limb weakness remained moderate even at very advanced ages, and cardiomyopathy did not develop due to the titin defect alone. The acquired results promote the correct identification of TMD, and the obtained trajectories of disease evolution can be used as natural history data for any therapeutic intervention.
Sections du résumé
BACKGROUND AND PURPOSE
Tibial muscular dystrophy (TMD) is a dominant late onset distal titinopathy. It was first described in Finnish patients 3 decades ago. TMD patients with several other TTN mutations occur in many European populations. In this retrospective study, we were able to obtain longitudinal follow-up data of the disease progression over 15 years in 137 TMD patients.
METHODS
We retrieved clinical data retrospectively from three examinations spanning a period of 15 years. The data were analyzed in R. Frequencies, percentages, and median values were used to describe data. Probability values were determined with the chi-squared test.
RESULTS
In the cohort, the first symptoms were walking difficulties (97.8%) and weakness in distal lower limbs (98.5%). The progression of the weakness in distal lower limbs was moderate, and in the proximal lower limbs and proximal upper limbs it was mild. The distal upper limbs were not affected. Magnetic resonance imaging results indicated fatty degeneration preferentially in lower leg anterior muscles, gluteus minimus, and hamstring muscles. Serum creatine kinase values in the cohort were mostly normal (40.7%) or mildly elevated (53.7%). The data suggest that 50% of patients need walking aids by the age of 88 years.
CONCLUSIONS
Despite individual variability of severity, the overall disability due to walking difficulties and upper limb weakness remained moderate even at very advanced ages, and cardiomyopathy did not develop due to the titin defect alone. The acquired results promote the correct identification of TMD, and the obtained trajectories of disease evolution can be used as natural history data for any therapeutic intervention.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1080-1088Informations de copyright
© 2023 European Academy of Neurology.
Références
Hackman P, Vihola A, Haravuori H, et al. Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the gene encoding the giant skeletal-muscle protein titin. Am J Hum Genet. 2002;71(3):492-500.
Udd B, Kaarianen H, Somer H. Muscular dystrophy with separate clinical phenotypes in a large family. Muscle Nerve. 1991;14(11):1050-1058.
Udd B et al. Tibial muscular dystrophy. Late adult-onset distal myopathy in 66 Finnish patients. Arch Neurol. 1993;50(6):604-608.
Pollazzon M, Suominen T, Penttilä S, et al. The first Italian family with tibial muscular dystrophy caused by a novel titin mutation. J Neurol. 2010;257(4):575-579.
Van den Bergh PYK, Bouquiaux O, Verellen C, et al. Tibial muscular dystrophy in a Belgian family. Ann Neurol. 2003;54(2):248-251.
Savarese M, Maggi L, Vihola A, et al. Interpreting genetic variants in titin in patients with muscle disorders. JAMA Neurol. 2018;75(5):557-565.
Savarese M, Johari M, Johnson K, et al. Improved criteria for the classification of titin variants in inherited skeletal myopathies. J Neuromuscul Dis. 2020;7(2):153-166.
Evila A, Vihola A, Sarparanta J, et al. Atypical phenotypes in titinopathies explained by second titin mutations. Ann Neurol. 2014;75(2):230-240.
Hackman P, Marchand S, Sarparanta J, et al. Truncating mutations in C-terminal titin may cause more severe tibial muscular dystrophy (TMD). Neuromuscul Disord. 2008;18(12):922-928.
Chemello F, Bassel-Duby R, Olson EN. Correction of muscular dystrophies by CRISPR gene editing. J Clin Invest. 2020;130(6):2766-2776.
Clemens PR, Rao VK, Connolly AM, et al. Safety, tolerability, and efficacy of Viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial. JAMA Neurol. 2020;77(8):982-991.
Duan D. Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy. Mol Ther. 2018;26(10):2337-2356.
Griffin DA, Pozsgai ER, Heller KN, Potter RA, Peterson EL, Rodino-Klapac LR. Preclinical systemic delivery of adeno-associated alpha-Sarcoglycan gene transfer for limb-girdle muscular dystrophy. Hum Gene Ther. 2021;32(7-8):390-404.
Marchetti GB, Valenti L, Torrente Y. Clinical determinants of disease progression in patients with beta-sarcoglycan gene mutations. Front Neurol. 2021;12:657949.
Murphy AP, Morrow J, Dahlqvist JR, et al. Natural history of limb girdle muscular dystrophy R9 over 6 years: searching for trial endpoints. Ann Clin Transl Neurol. 2019;6(6):1033-1045.
Pozsgai E, Griffin D, Potter R, et al. Unmet needs and evolving treatment for limb girdle muscular dystrophies. Neurodegener Dis Manag. 2021;11(5):411-429.
Udd B, Hackman P. Udd distal myopathy - tibial muscular dystrophy. In: Adam MP et al., eds. GeneReviews® [Internet]. University of Washington; 1993.
Chauveau C, Bonnemann CG, Julien C, et al. Recessive TTN truncating mutations define novel forms of core myopathy with heart disease. Hum Mol Genet. 2014;23(4):980-991.
Oates EC, Jones KJ, Donkervoort S, et al. Congenital Titinopathy: comprehensive characterization and pathogenic insights. Ann Neurol. 2018;83(6):1105-1124.
Perrin A, Juntas Morales R, Chapon F, et al. Novel dominant distal titinopathy phenotype associated with copy number variation. Ann Clin Transl Neurol. 2021;8(9):1906-1912.
Perrin A, Juntas Morales R, Rivier F, et al. The importance of an integrated genotype-phenotype strategy to unravel the molecular bases of titinopathies. Neuromuscul Disord. 2020;30(11):877-887.
Savarese M, Sarparanta J, Vihola A, Udd B, Hackman P. Increasing role of titin mutations in neuromuscular disorders. J Neuromuscul Dis. 2016;3(3):293-308.
Savarese M, Vihola A, Oates EC, et al. Genotype-phenotype correlations in recessive titinopathies. Genet Med. 2020;22(12):2029-2040.
Herman DS, Lam L, Taylor MRG, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012;366(7):619-628.
Schafer S, de Marvao A, Adami E, et al. Titin-truncating variants affect heart function in disease cohorts and the general population. Nat Genet. 2017;49(1):46-53.
Ware JS, Cook SA. Role of titin in cardiomyopathy: from DNA variants to patient stratification. Nat Rev Cardiol. 2018;15(4):241-252.